AstraZeneca

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU
JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU
Fierce Pharma
Amarin
Vascepa
Epanova
AstraZeneca
Acasti
Europe
Flag link:
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Flag link:
AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up
AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up
Fierce Pharma
AstraZeneca
Amarin
Vascepa
Epanova
clinical trials
Flag link:
AstraZeneca gets in on RNA game with MiNA research collaboration
AstraZeneca gets in on RNA game with MiNA research collaboration
Endpoints
AstraZeneca
RNA
MiNA
R&D
Flag link:
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
Forbes
FDA
Lynparza
AstraZeneca
pancreatic cancer
Flag link:
AstraZeneca kicks off 2020 with double win in US and China
AstraZeneca kicks off 2020 with double win in US and China
Pharmaforum
AstraZeneca
FDA
Farxiga
heart failure
China
Lokelma
hyperkalemia
Flag link:
3 Blockbuster Cancer Drug Launches to Watch in 2020
3 Blockbuster Cancer Drug Launches to Watch in 2020
Motley Fool
FDA
drug approvals
cancer
drug launches
AstraZeneca
Enhertu
Padcev
Seattle Genetics
BeiGene
Brukinsa
Flag link:
Corporate and regulatory developments over the Christmas period
Corporate and regulatory developments over the Christmas period
EP Vantage
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
Flag link:
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
BioSpace
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
Flag link:
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filing
Pharmaforum
FDA
AstraZeneca
Daiichi Sankyo
advanced breast cancer
Enhertu
Flag link:
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
BioPharma Dive
Daiichi Sankyo
AstraZeneca
FDA
drug approvals
breast cancer
trastuzumab deruxtecan
Flag link:
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Fierce Pharma
oncology
Rare Diseases
AstraZeneca
GSK
Alexion
Takeda
Soliris
Flag link:
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
Biopharma Dive
AstraZeneca
lupus
anifrolumab
GSK
Benlysta
Flag link:
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
advisory panels
Flag link:
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Pharmaforum
Novartis
Europe
GSK
Sanofi
AstraZeneca
Roche
Flag link:
AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia
AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia
Pharmaceutical Business Review
AstraZeneca
Seroquel
Seroquel XR
Russia
Europe
Cheplapharm
Flag link:
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
BRCA-mutated pancreatic cancer
pancreatic cancer
Flag link:
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
Farxiga
diabetes
AstraZeneca
heart failure
Flag link:
AZ’s Imfinzi approved in early lung cancer in China
AZ’s Imfinzi approved in early lung cancer in China
Pharmaforum
China
AstraZeneca
Imfinizi
non-small cell lung cancer
Flag link:
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
EP Vantage
breast cancer
AstraZeneca
Daiichi Sankyo
SABCS
trastuzumab deruxtecan
Flag link:

Pages